Lantheus Holdings (LNTH) is back in focus after U.S. regulators cleared PYLARIFY TruVu, a new formulation of its PSMA PET imaging agent for prostate cancer that is designed to support larger batch sizes and wider patient access.

The PYLARIFY TruVu approval lands after a sharp 1 day share price return of 10.27% and a 30 day share price return of 23.30%. However, the 1 year total shareholder return is a 27.27% decline, indicating short term momentum is improving after a tougher year for holders.

If this prostate cancer imaging news has caught your attention, it might be a good time to size up other healthcare opportunities using our screener of 32 healthcare AI stocks.

With Lantheus shares up strongly in recent weeks but still carrying an intrinsic discount estimate and trading below the average analyst target, you have to ask: is this a fresh entry point, or is the market already baking in future growth?

Most Popular Narrative: 5.4% Undervalued

The most followed narrative sees Lantheus Holdings trading below an implied fair value of $84.62, compared with the latest close at $80.01, and ties that gap tightly to earnings power and execution.

Multiple new product launches within the next 18 months, including the new F-18 PSMA PET, MK-6240, OCTEVY, and PNT2003, are set to diversify the revenue base, mitigate concentration risk, and open additional growth channels in oncology and neuroendocrine tumor imaging, supporting both top-line and future earnings expansion.

Curious what kind of revenue mix, margin profile, and earnings multiple need to line up to support that valuation gap, and how much execution room the narrative assumes?

Result: Fair Value of $84.62 (UNDERVALUED)

However, the key watchpoints are still PYLARIFY concentration and pricing pressure, as contract resets or reimbursement shifts could quickly challenge those earnings assumptions.

Next Steps

With sentiment in this article leaning cautiously optimistic, it makes sense to look at the numbers yourself and decide quickly what really matters. To see what is driving the more optimistic views, have a look at the 2 key rewards and weigh those positives against your own expectations.

Looking for more investment ideas?

If this has sharpened your focus on quality, do not stop here. Some of the best opportunities show up when you widen your search just a little.

• Target resilient income by checking out our list of 14 dividend fortresses that might suit investors who care about regular cash flow and staying power.
• Hunt for value by scanning our 46 high quality undervalued stocks that currently look mispriced based on fundamentals and may warrant a closer look.
• Spot potential early movers by reviewing the screener containing 23 high quality undiscovered gems before they sit firmly on everyone else's radar.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.